BIOS Key Stats
- BioScrip To Present At Jefferies 2013 Global Healthcare Conference PR Newswire May 23
- Do These Tuesday Upgrades Present a Buying Opportunity? Fool May 23
- Shorts Are Covering 3 Stocks Undervalued By EPS Trends May 21
- Movers roundup: Tesla, BioScrip May 21
- BioScrip rises on positive analyst expectations May 21
- Jefferies Starts BioScrip (BIOS) at Buy, $17 PT Street Insider May 21
- Nasdaq stocks posting largest volume increases May 15
- Prominent Hedge Fund Prescott Group Buying Some Little-Known Plays May 14
- Are You Missing Something Easy at BioScrip? Fool May 14
- Investing In Pharmacy Stocks Could Be The Next Major Play May 13
BIOS Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). BioScrip is up 99.41% over the last year vs S&P 500 Total Return up 28.03%, Echo Therapeutics down 68.21%, and Alimera Sciences up 69.08%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Pro Ratings for BIOS
Pro Report PDF for BIOS
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download BIOS Pro Report PDF
Pro Strategies Featuring BIOS
Did BioScrip make it into our Pro Portfolio Strategies?